查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1842142

全球新生兒毒理學檢測市場：市場規模、佔有率、趨勢分析（按檢體、技術、藥物、最終用途和地區分類）、細分市場預測（2025-2033 年）

Neonatal Toxicology Market Size, Share & Trends Analysis Report By Specimen (Urine, Umbilical Cord, Meconium), By Technology (Mass spectroscopy, Immunoassay), By Drug (Cannabinoids, Opioids), By End-use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

新生兒毒理學檢測：市場概覽

全球新生兒毒理學檢測市場預計在 2024 年達到 2.8092 億美元，預計到 2033 年將達到 7.0132 億美元，2025 年至 2033 年的複合年成長率為 10.73%。

這一成長歸因於孕婦吸毒現象的增加，以及更靈敏、更特異性的檢測方法的發展。

根據世界衛生組織的估計，2022年將有230萬名兒童在出生後的前20天內死亡，相當於每天約有6500名新生兒死亡，佔5歲以下兒童死亡總數的47%。此外，政府舉措的增加和新生兒篩檢計畫的普及可能會在預測期內推動市場成長。

孕期母體藥物濫用增加與新生兒鴉片類藥物戒斷症候群（NOWS）病例的急劇增加同時發生。母體藥物濫用，尤其是鴉片類藥物濫用的增加，導致了NOWS發生率的上升。 NOWS是一種新生兒在產前接觸藥物後出現戒斷症狀的疾病。尼古丁是懷孕期間最常用的藥物，其次是酒精、大麻和古柯鹼。然而，一些研究表明，多種藥物濫用率高達50%。近年來，美國懷孕鴉片類藥物的使用量增加了五倍，這與處方箋鴉片類藥物濫用的「流行」不謀而合。根據美國國家醫學圖書館公佈的數據，美國孕婦藥物濫用仍然是一個緊迫的公共衛生問題，近6%的孕婦使用非法藥物，超過8%的孕婦飲酒，超過16%的孕婦吸菸。因此，超過 38 萬、55 萬，甚至可能有 100 萬胎兒在子宮內接觸到非法藥物、酒精和菸草。

目前正在開發先進的分析技術，用於識別和檢測各種生物樣本中的新生兒藥物暴露及其代謝物。急性暴露可透過尿液、血液和口腔液等基質檢測，通常在短時間內即可檢測到；而慢性暴露則可透過毛髮、糞便和牙齒等基質檢測。糞便分析已成為新生兒藥物檢測的黃金標準，因為它比傳統的尿液檢查或血液檢測更長時間地檢測到產前藥物暴露。研究人員也正在探索臍帶組織分析的潛力，該方法與胎糞檢測具有相似的優勢，但樣本採集更簡單、更標準化。

市場的另一個特點是質譜（MS）和酵素連結檢測等技術的進步。這些技術在早期發現先天性代謝紊亂、預防死亡和促進健康發育方面發揮關鍵作用。質譜技術，特別是液相層析法串聯式質譜質譜（LC-MS/MS），因其能夠檢測和定量極低濃度的多種物質，已成為黃金標準。這些方法可以同時篩檢多種藥物及其代謝物，從而提高檢測的廣度和準確性。

各國政府通常會制定法規和指南，鼓勵或強制在特定情況下對新生兒進行藥物檢測，例如懷疑母親在懷孕期間濫用藥物時。例如，在美國，兒童虐待預防和治療方法(CAPTA) 正在鼓勵各州制定計劃，以滿足接觸過藥物的新生兒的需求。預計全球範圍內的此類舉措將在預測期內推動市場發展。

目錄

第1章 分析方法和範圍

第2章執行摘要

第3章 新生兒毒理學檢測市場：促進因素、趨勢與範圍

  • 市場關聯性展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 新生兒毒理學檢測市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL 分析

第4章 新生兒毒理學檢測市場：依檢體的估算與趨勢分析

  • 按檢體的市場佔有率（2024 年和 2033 年）
  • 細分儀表板
  • 全球新生兒毒理學檢測市場展望（按檢體）
  • 市場規模預測及趨勢分析（2021-2033）
    • 尿
    • 臍帶
    • 胎糞
    • 其他

第5章 新生兒毒理學檢測市場：依技術分類的估算與趨勢分析

  • 按技術分類的市場佔有率（2024 年和 2033 年）
  • 細分儀表板
  • 全球新生兒毒理學檢測市場展望（依技術分類）
  • 市場規模預測及趨勢分析（2021-2033）
    • 質譜分析
    • 免疫檢測

第6章 新生兒毒理學檢測市場：依藥物類型分類的估算與趨勢分析

  • 按藥物類型分類的市場佔有率（2024 年和 2033 年）
  • 細分儀表板
  • 全球新生兒毒理學篩檢市場展望（按藥物類型分類）
  • 市場規模預測及趨勢分析（2021-2033）
    • 大麻素
    • 鴉片類藥物
    • 古柯鹼
    • 苯二氮平類藥物
    • 安非他命
    • 其他非法藥物

第7章 新生兒毒理學檢測市場：依最終用途分類的估算與趨勢分析

  • 按最終用途分類的市場佔有率（2024 年和 2033 年）
  • 細分儀表板
  • 全球新生兒毒理學檢測市場依最終用途展望
  • 市場規模預測及趨勢分析（2021-2033）
    • 醫院
    • 臨床實驗室
    • 其他

第8章：新生兒毒理學檢測市場：區域估算與趨勢分析

  • 按地區分類的市場佔有率分析（2024 年和 2033 年）
  • 市場概覽：按地區
  • 全球市場概覽：按地區分類
  • 市場規模預測及趨勢分析（2021-2033）
  • 北美洲
    • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭情勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商概況
    • 主要經銷商和通路合作夥伴名單
    • 主要客戶
    • 主要企業市佔率分析（2023）
    • Quest Diagnostics Incorporated
    • USDTL
    • Quidel Corporation
    • Thermo Fisher Scientific, Inc.
    • Omega Laboratories, Inc.
    • Bio-Rad Laboratories, Inc.
    • Agilent Technologies, Inc.
    • Laboratory Corporation of America Holdings
    • Clinical Reference Laboratory, Inc.
    • Cordant Health Solutions
    • Arup Consult
    • Cordant Health Solutions
Product Code: GVR-4-68040-358-5

Neonatal Toxicology Market Summary

The global neonatal toxicology market size was estimated at USD 280.92 million in 2024 and is projected to reach USD 701.32 million by 2033, growing at a CAGR of 10.73% from 2025 to 2033. This growth is attributed to the increasing incidence of maternal drug use, along with development of more sensitive and specific testing methods.

The newborn mortality is also a rising concern governing the market growth, as per WHO estimates 2.3 million children died in the first 20 days of life in 2022, with estimated 6500 newborn deaths per day, accounting to 47% of all child deaths below the age of 5 years. Furthermore, increasing government initiatives and availability of newborn screening programs are likely to drive the market over the forecast period.

The rising increase in maternal drug use during pregnancy has coincided with a surge in cases of neonatal opioid withdrawal syndrome (NOWS). This rise in maternal substance use, particularly opioids, has led to a concomitant increase in NOWS, a condition in which newborns experience withdrawal symptoms due to prenatal exposure to substances. The most commonly used substance in pregnancy is nicotine, followed by alcohol, marijuana, and cocaine. However, polysubstance use is as high as 50% in some studies. Notably, there has been five times increase in opioid use in pregnancy in the U S in recent years, coinciding with an "epidemic" of opioid prescription misuse. According to the data published by National Library of Medicine, substance abuse among pregnant women remains a pressing public health issue in the U.S, with nearly 6% using illicit drugs, over 8% drinking alcohol, and more than 16% smoking cigarettes. This has led to a staggering number of exposed offspring, with over 380,000 babies exposed to illicit substances, over 550,000 exposed to alcohol, and more than one million exposed to tobacco while in the womb.

Advanced analytical techniques have been created to identify and detect neonatal drug exposure and their metabolites in various biological samples. These biological samples have distinct windows of detection for exposure: acute exposure can be detected in matrices such as urine, blood, and oral fluid, typically within a short timeframe, while chronic exposure can be detected in matrices such as hair, meconium, or teeth, which provide a longer window of detection. Meconium analysis has gained prominence as a gold standard for drug testing in newborns that provides a longer window of detection for prenatal drug exposure compared to traditional urine or blood tests. Researchers are also exploring the potential of umbilical cord tissue analysis, which offers similar benefits to meconium testing but with easier and more standardized sample collection.

The market is further characterized by advancements in technology including mass spectrometry (MS), enzyme-based assays, and others. These technologies play a crucial role in detecting congenital or inborn abnormalities of metabolism at an early stage, preventing death, and promoting healthy development. Mass spectrometry techniques, particularly liquid chromatography-tandem mass spectrometry (LC-MS/MS), have emerged as gold standards due to their ability to detect and quantify a wide range of substances at very low concentrations. These methods allow for the simultaneous screening of multiple drugs and their metabolites, improving both the breadth and accuracy of testing.

Governments often establish regulations and guidelines that encourage or mandate drug testing for newborns in certain situations, such as when there's suspicion of maternal substance abuse during pregnancy. For instance, in the U.S., the Child Abuse Prevention and Treatment Act (CAPTA) encourages states to develop plans to address the needs of substance-exposed infants. Such initiatives across global regions is poised to drive the market in forecast period.

Global Neonatal Toxicology Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global neonatal toxicology market report on the basis of specimen, technology, drug, end use, and region:

  • Specimen Outlook (Revenue, USD Million, 2021 - 2031)
  • Urine
  • Umbilical Cord
  • Meconium
  • Others
  • Technology Outlook (Revenue, USD Million, 2021 - 2031)
  • Mass spectroscopy
  • Immunoassay
  • Drug Outlook (Revenue, USD Million, 2021 - 2031)
  • Cannabinoids
  • Opioids
  • Cocaine
  • Benzodiazepines
  • Amphetamines
  • Other illicit drugs
  • End Use Outlook (Revenue, USD Million, 2021 - 2031)
  • Hospitals
  • Clinical Laboratories
  • Others
  • Regional Outlook (Revenue in USD Million, 2021 - 2031)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Specimen
    • 1.2.2. Technology
    • 1.2.3. Drug
    • 1.2.4. End User
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Specimen outlook
    • 2.2.2. Technology outlook
    • 2.2.3. Drug outlook
    • 2.2.4. End User outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Neonatal Toxicology Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. High prevalence of substance abuse
      • 3.2.1.2. Stringent laws mandating alcohol and drug testing
      • 3.2.1.3. Increasing government initiatives to monitor substance abuse
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Neonatal toxicology is considered a violation of privacy rights in some countries
  • 3.3. Neonatal Toxicology Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Neonatal Toxicology Market: Specimen Estimates & Trend Analysis

  • 4.1. Specimen Market Share, 2024 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Global Neonatal Toxicology Market by Specimen Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 4.4.1. Urine
      • 4.4.1.1. Urine market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2. Umbilical Cord
      • 4.4.2.1. Umbilical cord market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.3. Meconium
      • 4.4.3.1. Meconium market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Neonatal Toxicology Market: Technology Estimates & Trend Analysis

  • 5.1. Technology Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Neonatal Toxicology Market by Technology Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 5.4.1. Mass spectroscopy
      • 5.4.1.1. Mass spectroscopy market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.2. Immunoassay
      • 5.4.2.1. Immunoassay market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Neonatal Toxicology Market: Drug type Estimates & Trend Analysis

  • 6.1. Drug type Market Share, 2024 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global Neonatal Toxicology Market by Drug type Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 6.4.1. Cannabinoids
      • 6.4.1.1. Cannabinoids Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.2. Opioids
      • 6.4.2.1. Opioids Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.3. Cocaine
      • 6.4.3.1. Cocaine Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.4. Benzodiazepines
      • 6.4.4.1. Benzodiazepines market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.5. Amphetamines
      • 6.4.5.1. Amphetamines Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.6. Other illicit drugs
      • 6.4.6.1. Other illicit drugs Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Neonatal Toxicology Market: End User Estimates & Trend Analysis

  • 7.1. End User Market Share, 2024 & 2033
  • 7.2. Segment Dashboard
  • 7.3. Global Neonatal Toxicology Market by End User Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 7.4.1. Hospitals
      • 7.4.1.1. Hospitals Market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.2. Clinical Laboratories
      • 7.4.2.1. Clinical Laboratories Market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.3. Others
      • 7.4.3.1. Others Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Neonatal Toxicology Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 8.5. North America
    • 8.5.1. North America
    • 8.5.2. U.S.
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.3. Canada
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.4. Mexico
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6. Europe
    • 8.6.1. Europe
    • 8.6.2. UK
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ Reimbursement
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.3. Germany
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ Reimbursement
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.4. France
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ Reimbursement
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.5. Italy
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ Reimbursement
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.6. Spain
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.7. Norway
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.8. Sweden
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.9. Denmark
      • 8.6.9.1. Key country dynamics
      • 8.6.9.2. Regulatory framework/ Reimbursement
      • 8.6.9.3. Competitive scenario
      • 8.6.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Asia Pacific
    • 8.7.2. Japan
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ Reimbursement
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.3. China
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ Reimbursement
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.4. India
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ Reimbursement
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.5. Australia
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/ Reimbursement
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.6. South Korea
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/ Reimbursement
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.7. Thailand
      • 8.7.7.1. Key country dynamics
      • 8.7.7.2. Regulatory framework/ Reimbursement
      • 8.7.7.3. Competitive scenario
      • 8.7.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Latin America
    • 8.8.2. Brazil
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.8.3. Argentina
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework/ Reimbursement
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9. MEA
    • 8.9.1. MEA
    • 8.9.2. South Africa
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/ Reimbursement
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.3. Saudi Arabia
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/ Reimbursement
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.4. UAE
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/ Reimbursement
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.5. Kuwait
      • 8.9.5.1. Key country dynamics
      • 8.9.5.2. Regulatory framework
      • 8.9.5.3. Competitive scenario
      • 8.9.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2023
    • 9.3.4. Quest Diagnostics Incorporated
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Others benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. USDTL
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Others benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Quidel Corporation
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Others benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Thermo Fisher Scientific, Inc.
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Others benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Omega Laboratories, Inc.
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Others benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Bio-Rad Laboratories, Inc.
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Others benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Agilent Technologies, Inc.
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Others benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Laboratory Corporation of America Holdings
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Others benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Clinical Reference Laboratory, Inc.
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Others benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Cordant Health Solutions
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Others benchmarking
      • 9.3.13.4. Strategic initiatives
    • 9.3.14. Arup Consult
      • 9.3.14.1. Company overview
      • 9.3.14.2. Financial performance
      • 9.3.14.3. Others benchmarking
      • 9.3.14.4. Strategic initiatives
    • 9.3.15. Cordant Health Solutions
      • 9.3.15.1. Company overview
      • 9.3.15.2. Financial performance
      • 9.3.15.3. Others benchmarking
      • 9.3.15.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America neonatal toxicology market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America neonatal toxicology market, by specimen, 2021 - 2033 (USD Million)
  • Table 4 North America neonatal toxicology market, by technology, 2021 - 2033 (USD Million)
  • Table 5 North America neonatal toxicology market, by drug, 2021 - 2033 (USD Million)
  • Table 6 North America neonatal toxicology market, by end use, 2021 - 2033 (USD Million)
  • Table 7 U.S. neonatal toxicology market, by specimen, 2021 - 2033 (USD Million)
  • Table 8 U.S. neonatal toxicology market, by technology, 2021 - 2033 (USD Million)
  • Table 9 U.S. neonatal toxicology market, by drug, 2021 - 2033 (USD Million)
  • Table 10 U.S. neonatal toxicology market, by end use, 2021 - 2033 (USD Million)
  • Table 11 Canada neonatal toxicology market, by specimen, 2021 - 2033 (USD Million)
  • Table 12 Canada neonatal toxicology market, by technology, 2021 - 2033 (USD Million)
  • Table 13 Canada neonatal toxicology market, by drug, 2021 - 2033 (USD Million)
  • Table 14 Canada neonatal toxicology market, by end use, 2021 - 2033 (USD Million)
  • Table 15 Mexico neonatal toxicology market, by specimen, 2021 - 2033 (USD Million)
  • Table 16 Mexico neonatal toxicology market, by technology, 2021 - 2033 (USD Million)
  • Table 17 Mexico neonatal toxicology market, by drug, 2021 - 2033 (USD Million)
  • Table 18 Mexico neonatal toxicology market, by end use, 2021 - 2033 (USD Million)
  • Table 19 Europe neonatal toxicology market, by region, 2021 - 2033 (USD Million)
  • Table 20 Europe neonatal toxicology market, by specimen, 2021 - 2033 (USD Million)
  • Table 21 Europe neonatal toxicology market, by technology, 2021 - 2033 (USD Million)
  • Table 22 Europe neonatal toxicology market, by drug, 2021 - 2033 (USD Million)
  • Table 23 Europe neonatal toxicology market, by end use, 2021 - 2033 (USD Million)
  • Table 24 Germany neonatal toxicology market, by specimen, 2021 - 2033 (USD Million)
  • Table 25 Germany neonatal toxicology market, by technology, 2021 - 2033 (USD Million)
  • Table 26 Germany neonatal toxicology market, by drug, 2021 - 2033 (USD Million)
  • Table 27 Germany neonatal toxicology market, by end use, 2021 - 2033 (USD Million)
  • Table 28 UK neonatal toxicology market, by specimen, 2021 - 2033 (USD Million)
  • Table 29 UK neonatal toxicology market, by technology, 2021 - 2033 (USD Million)
  • Table 30 UK neonatal toxicology market, by drug, 2021 - 2033 (USD Million)
  • Table 31 UK neonatal toxicology market, by end use, 2021 - 2033 (USD Million)
  • Table 32 France neonatal toxicology market, by specimen, 2021 - 2033 (USD Million)
  • Table 33 France neonatal toxicology market, by technology, 2021 - 2033 (USD Million)
  • Table 34 France neonatal toxicology market, by drug, 2021 - 2033 (USD Million)
  • Table 35 France neonatal toxicology market, by end use, 2021 - 2033 (USD Million)
  • Table 36 Italy neonatal toxicology market, by specimen, 2021 - 2033 (USD Million)
  • Table 37 Italy neonatal toxicology market, by technology, 2021 - 2033 (USD Million)
  • Table 38 Italy neonatal toxicology market, by drug, 2021 - 2033 (USD Million)
  • Table 39 Italy neonatal toxicology market, by end use, 2021 - 2033 (USD Million)
  • Table 40 Spain neonatal toxicology market, by specimen, 2021 - 2033 (USD Million)
  • Table 41 Spain neonatal toxicology market, by technology, 2021 - 2033 (USD Million)
  • Table 42 Spain neonatal toxicology market, by drug, 2021 - 2033 (USD Million)
  • Table 43 Spain neonatal toxicology market, by end use, 2021 - 2033 (USD Million)
  • Table 44 Denmark neonatal toxicology market, by specimen, 2021 - 2033 (USD Million)
  • Table 45 Denmark neonatal toxicology market, by technology, 2021 - 2033 (USD Million)
  • Table 46 Denmark neonatal toxicology market, by drug, 2021 - 2033 (USD Million)
  • Table 47 Denmark neonatal toxicology market, by end use, 2021 - 2033 (USD Million)
  • Table 48 Sweden neonatal toxicology market, by specimen, 2021 - 2033 (USD Million)
  • Table 49 Sweden neonatal toxicology market, by technology, 2021 - 2033 (USD Million)
  • Table 50 Sweden neonatal toxicology market, by drug, 2021 - 2033 (USD Million)
  • Table 51 Sweden neonatal toxicology market, by end use, 2021 - 2033 (USD Million)
  • Table 52 Norway neonatal toxicology market, by specimen, 2021 - 2033 (USD Million)
  • Table 53 Norway neonatal toxicology market, by technology, 2021 - 2033 (USD Million)
  • Table 54 Norway neonatal toxicology market, by drug, 2021 - 2033 (USD Million)
  • Table 55 Norway neonatal toxicology market, by end use, 2021 - 2033 (USD Million)
  • Table 56 Asia Pacific neonatal toxicology market, by region, 2021 - 2033 (USD Million)
  • Table 57 Asia Pacific neonatal toxicology market, by specimen, 2021 - 2033 (USD Million)
  • Table 58 Asia Pacific neonatal toxicology market, by technology, 2021 - 2033 (USD Million)
  • Table 59 Asia Pacific neonatal toxicology market, by drug, 2021 - 2033 (USD Million)
  • Table 60 Asia Pacific neonatal toxicology market, by end use, 2021 - 2033 (USD Million)
  • Table 61 China neonatal toxicology market, by specimen, 2021 - 2033 (USD Million)
  • Table 62 China neonatal toxicology market, by technology, 2021 - 2033 (USD Million)
  • Table 63 China neonatal toxicology market, by drug, 2021 - 2033 (USD Million)
  • Table 64 China neonatal toxicology market, by end use, 2021 - 2033 (USD Million)
  • Table 65 Japan neonatal toxicology market, by specimen, 2021 - 2033 (USD Million)
  • Table 66 Japan neonatal toxicology market, by technology, 2021 - 2033 (USD Million)
  • Table 67 Japan neonatal toxicology market, by drug, 2021 - 2033 (USD Million)
  • Table 68 Japan neonatal toxicology market, by end use, 2021 - 2033 (USD Million)
  • Table 69 India neonatal toxicology market, by specimen, 2021 - 2033 (USD Million)
  • Table 70 India neonatal toxicology market, by technology, 2021 - 2033 (USD Million)
  • Table 71 India neonatal toxicology market, by drug, 2021 - 2033 (USD Million)
  • Table 72 India neonatal toxicology market, by end use, 2021 - 2033 (USD Million)
  • Table 73 South Korea neonatal toxicology market, by specimen, 2021 - 2033 (USD Million)
  • Table 74 South Korea neonatal toxicology market, by technology, 2021 - 2033 (USD Million)
  • Table 75 South Korea neonatal toxicology market, by drug, 2021 - 2033 (USD Million)
  • Table 76 South Korea neonatal toxicology market, by end use, 2021 - 2033 (USD Million)
  • Table 77 Australia neonatal toxicology market, by specimen, 2021 - 2033 (USD Million)
  • Table 78 Australia neonatal toxicology market, by technology, 2021 - 2033 (USD Million)
  • Table 79 Australia neonatal toxicology market, by drug, 2021 - 2033 (USD Million)
  • Table 80 Australia neonatal toxicology market, by end use, 2021 - 2033 (USD Million)
  • Table 81 Thailand neonatal toxicology market, by specimen, 2021 - 2033 (USD Million)
  • Table 82 Thailand neonatal toxicology market, by technology, 2021 - 2033 (USD Million)
  • Table 83 Thailand neonatal toxicology market, by drug, 2021 - 2033 (USD Million)
  • Table 84 Thailand neonatal toxicology market, by end use, 2021 - 2033 (USD Million)
  • Table 85 Latin America neonatal toxicology market, by specimen, 2021 - 2033 (USD Million)
  • Table 86 Latin America neonatal toxicology market, by technology, 2021 - 2033 (USD Million)
  • Table 87 Latin America neonatal toxicology market, by drug, 2021 - 2033 (USD Million)
  • Table 88 Latin America neonatal toxicology market, by end use, 2021 - 2033 (USD Million)
  • Table 89 Brazil neonatal toxicology market, by specimen, 2021 - 2033 (USD Million)
  • Table 90 Brazil neonatal toxicology market, by technology, 2021 - 2033 (USD Million)
  • Table 91 Brazil neonatal toxicology market, by drug, 2021 - 2033 (USD Million)
  • Table 92 Brazil neonatal toxicology market, by end use, 2021 - 2033 (USD Million)
  • Table 93 Argentina neonatal toxicology market, by specimen, 2021 - 2033 (USD Million)
  • Table 94 Argentina neonatal toxicology market, by technology, 2021 - 2033 (USD Million)
  • Table 95 Argentina neonatal toxicology market, by drug, 2021 - 2033 (USD Million)
  • Table 96 Argentina neonatal toxicology market, by end use, 2021 - 2033 (USD Million)
  • Table 97 MEA neonatal toxicology market, by region, 2021 - 2033 (USD Million)
  • Table 98 MEA neonatal toxicology market, by specimen, 2021 - 2033 (USD Million)
  • Table 99 MEA neonatal toxicology market, by technology, 2021 - 2033 (USD Million)
  • Table 100 MEA neonatal toxicology market, by drug, 2021 - 2033 (USD Million)
  • Table 101 MEA neonatal toxicology market, by end use, 2021 - 2033 (USD Million)
  • Table 102 South Africa neonatal toxicology market, by specimen, 2021 - 2033 (USD Million)
  • Table 103 South Africa neonatal toxicology market, by technology, 2021 - 2033 (USD Million)
  • Table 104 South Africa neonatal toxicology market, by drug, 2021 - 2033 (USD Million)
  • Table 105 South Africa neonatal toxicology market, by end use, 2021 - 2033 (USD Million)
  • Table 106 Saudi Arabia neonatal toxicology market, by specimen, 2021 - 2033 (USD Million)
  • Table 107 Saudi Arabia neonatal toxicology market, by technology, 2021 - 2033 (USD Million)
  • Table 108 Saudi Arabia neonatal toxicology market, by drug, 2021 - 2033 (USD Million)
  • Table 109 Saudi Arabia neonatal toxicology market, by end use, 2021 - 2033 (USD Million)
  • Table 110 UAE neonatal toxicology market, by specimen, 2021 - 2033 (USD Million)
  • Table 111 UAE neonatal toxicology market, by technology, 2021 - 2033 (USD Million)
  • Table 112 UAE neonatal toxicology market, by drug, 2021 - 2033 (USD Million)
  • Table 113 UAE neonatal toxicology market, by end use, 2021 - 2033 (USD Million)
  • Table 114 Kuwait neonatal toxicology market, by specimen, 2021 - 2033 (USD Million)
  • Table 115 Kuwait neonatal toxicology market, by technology, 2021 - 2033 (USD Million)
  • Table 116 Kuwait neonatal toxicology market, by drug, 2021 - 2033 (USD Million)
  • Table 117 Kuwait neonatal toxicology market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Neonatal toxicology market: market outlook
  • Fig. 14 Neonatal toxicology competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Neonatal toxicology market driver impact
  • Fig. 20 Neonatal toxicology market restraint impact
  • Fig. 21 Neonatal toxicology market strategic initiatives analysis
  • Fig. 22 Neonatal toxicology market: Specimen movement analysis
  • Fig. 23 Neonatal toxicology market: Specimen outlook and key takeaways
  • Fig. 24 Urine market estimates and forecast, 2021 - 2033
  • Fig. 25 Umbilical cord estimates and forecast, 2021 - 2033
  • Fig. 26 Meconium market estimates and forecast, 2021 - 2033
  • Fig. 27 Others market estimates and forecast, 2021 - 2033
  • Fig. 28 Neonatal toxicology Market: Technology movement analysis
  • Fig. 29 Neonatal toxicology market: Technology outlook and key takeaways
  • Fig. 30 Mass spectroscopy market estimates and forecasts, 2021 - 2033
  • Fig. 31 Immunoassay market estimates and forecasts,2021 - 2033
  • Fig. 32 Neonatal toxicology market: Drug movement analysis
  • Fig. 33 Neonatal toxicology market: Drug outlook and key takeaways
  • Fig. 34 Cannabinoids market estimates and forecast, 2021 - 2033
  • Fig. 35 Opioids estimates and forecast, 2021 - 2033
  • Fig. 36 Amphetamines market estimates and forecast, 2021 - 2033
  • Fig. 37 Cocaine market estimates and forecast, 2021 - 2033
  • Fig. 38 Benzodiazepines market estimates and forecast, 2021 - 2033
  • Fig. 39 Others illicit drugs market estimates and forecast, 2021 - 2033
  • Fig. 40 Neonatal toxicology market: End use movement analysis
  • Fig. 41 Neonatal toxicology market: End use outlook and key takeaways
  • Fig. 42 Hospitals market estimates and forecasts, 2021 - 2033
  • Fig. 43 Clinical Laboratories market estimates and forecasts,2021 - 2033
  • Fig. 44 Others market estimates and forecasts, 2021 - 2033
  • Fig. 45 Global neonatal toxicology market: Regional movement analysis
  • Fig. 46 Global neonatal toxicology market: Regional outlook and key takeaways
  • Fig. 47 Global neonatal toxicology market share and leading players
  • Fig. 48 North America market share and leading players
  • Fig. 49 Europe market share and leading players
  • Fig. 50 Asia Pacific market share and leading players
  • Fig. 51 Latin America market share and leading players
  • Fig. 52 Middle East & Africa market share and leading players
  • Fig. 53 North America, by country
  • Fig. 54 North America
  • Fig. 55 North America market estimates and forecasts, 2021 - 2033
  • Fig. 56 U.S. key country dynamics
  • Fig. 57 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 58 Canada key country dynamics
  • Fig. 59 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 60 Mexico key country dynamics
  • Fig. 61 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 62 Europe
  • Fig. 63 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 64 UK key country dynamics
  • Fig. 65 UK market estimates and forecasts, 2021 - 2033
  • Fig. 66 Germany key country dynamics
  • Fig. 67 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 68 France key country dynamics
  • Fig. 69 France market estimates and forecasts, 2021 - 2033
  • Fig. 70 Italy key country dynamics
  • Fig. 71 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 72 Spain key country dynamics
  • Fig. 73 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 74 Denmark key country dynamics
  • Fig. 75 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 76 Sweden key country dynamics
  • Fig. 77 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 78 Norway key country dynamics
  • Fig. 79 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 80 Asia Pacific
  • Fig. 81 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 82 China key country dynamics
  • Fig. 83 China market estimates and forecasts, 2021 - 2033
  • Fig. 84 Japan key country dynamics
  • Fig. 85 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 86 India key country dynamics
  • Fig. 87 India market estimates and forecasts, 2021 - 2033
  • Fig. 88 Thailand key country dynamics
  • Fig. 89 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 90 South Korea key country dynamics
  • Fig. 91 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 92 Australia key country dynamics
  • Fig. 93 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 94 Latin America
  • Fig. 95 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 96 Brazil key country dynamics
  • Fig. 97 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 98 Argentina key country dynamics
  • Fig. 99 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 100 Middle East and Africa
  • Fig. 101 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 102 South Africa key country dynamics
  • Fig. 103 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 104 Saudi Arabia key country dynamics
  • Fig. 105 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 106 UAE key country dynamics
  • Fig. 107 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 108 Kuwait key country dynamics
  • Fig. 109 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 110 Market share of key market players- Neonatal toxicology market